Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 411

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Marek's disease virus: from miasma to model

Osterrieder, Nikolaus, Kamil, Jeremy P., Schumacher, Daniel, Tischer, B. Karsten, Trapp, Sascha·2006·Nature Reviews Microbiology
DOI 10.1038/nrmicro1382
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrmicro1382

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 93

  1. Marek, J. Multiple Nervenentzündung (Polyneuritis) bei Hühnern. Dtsch. Tierärztl. Wochenschr. 15, 417–421 (1907). The first description of the disease.
  2. Bacon, L. D., Witter, R. L. & Silva, R. F. Characterization and experimental reproduction of peripheral neuropathy in White Leghorn chickens. Avian Pathol. 30, 487–499 (2001). · doi:10.1080/03079450120078680
  3. Gimeno, I. M., Witter, R. L. & Reed, W. M. Four distinct neurologic syndromes in Marek's disease: effect of viral strain and pathotype. Avian Dis. 43, 721–737 (1999). · doi:10.2307/1592741
  4. Pappenheimer, A. W., Dunn, L C. & Cone, V. Studies on fowl paralysis (Neurolymphomatosis gallinarum). I. Clinical features and pathology. J. Exp. Med. 46, 63–86 (1929). · doi:10.1084/jem.49.1.63
  5. Pappenheimer, A. W., Dunn, L. C. & Seidlin, S. M. Studies on fowl paralysis (Neurolymphomatosis gallinarum). II. Transmission experiments. J. Exp. Med. 49, 87–102 (1929). In two back-to-back papers, the early findings of Marek are extended and a link is established between polyneuritis and visceral lymphoma. In addition, the first description of the infectious nature of the disease. · doi:10.1084/jem.49.1.87
  6. Biggs, P. M. History of Marek's disease. In Marek's Disease (ed. Hirai, K.) 1–24 (Springer, Berlin, 2001).
  7. Churchill, A. E., Payne, L. N. & Chubb, R. C. Immunization against Marek's disease using a live attenuated virus. Nature 221, 744–747 (1969). The use of attenuated MDV as a highly effective antitumour vaccine is described. This report is the first description of a highly efficient antitumour vaccine only two years after the identification and isolation of the agent. · doi:10.1038/221744a0
  8. Churchill, A. E. & Biggs, P. M. Herpes-type virus isolated in cell culture from tumors of chickens with Marek's disease. II. Studies in vivo. J. Natl Cancer Inst. 41, 951–956 (1968).
  9. Churchill, A. E. Herpes-type virus isolated in cell culture from tumors of chickens with Marek's disease. I. Studies in cell culture. J. Natl Cancer Inst. 41, 939–950 (1968).
  10. Churchill, A. E. & Biggs, P. M. Agent of Marek's disease in tissue culture. Nature 215, 528–530 (1967). This paper describes the isolation and unequivocal identification of the MD agent as a herpesvirus. · doi:10.1038/215528a0
  11. Epstein, M. A., Achong, B. G., Churchill, A. E. & Biggs, P. M. Structure and development of the herpes-types virus of Marek's disease. J. Natl Cancer Inst. 41, 805–820 (1968).
  12. Okazaki, W., Purchase, H. G. & Burmester, B. R. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis. 14, 413–429 (1970). · doi:10.2307/1588488
  13. Cebrian, J., Kaschka-Dierich, C., Berthelot, N. & Sheldrick, P. Inverted repeat nucleotide sequences in the genomes of Marek disease virus and the herpesvirus of the turkey. Proc. Natl Acad. Sci. USA 79, 555–558 (1982). · doi:10.1073/pnas.79.2.555
  14. Fukuchi, K., Sudo, M., Lee, Y. S., Tanaka, A. & Nonoyama, M. Structure of Marek's disease virus DNA: detailed restriction enzyme map. J. Virol. 51, 102–109 (1984). The starting point for MDV genetics and further confirmation of the virus' classification in the α -herpesvirus subfamily. · doi:10.1128/jvi.51.1.102-109.1984
  15. Osterrieder, N. & Vautherot, J. F. The genome content of Marek's disease virus. In Marek's Disease (eds Davison, T. F. & Nair, V. K.) 17–31 (Elsevier, London, 2004). · doi:10.1016/b978-012088379-0/50007-4
  16. Davison, A. Comments on the phylogenetics and evolution of herpesviruses and other large DNA viruses. Virus Res. 82, 127–132 (2002). · doi:10.1016/s0168-1702(01)00400-2
  17. Adldinger, H. K. & Calnek, B. W. Pathogenesis of Marek's disease: early distribution of virus and viral antigens in infected chickens. J. Natl Cancer Inst. 50, 1287–1298 (1973). Gives the first account of the shedding of MDV in the feather follicle epithelia. This finding was instrumental in understanding the epidemiology and spread of the disease. · doi:10.1093/jnci/50.5.1287
  18. Calnek, B. W. Influence of age at exposure on the pathogenesis of Marek's disease. J. Natl Cancer Inst. 51, 929–939 (1973). · doi:10.1093/jnci/51.3.929
  19. Schat, K. A., Calnek, B. W., Fabricant, J. & Abplanalp, H. Influence of oncogenicity of Marek' disease virus on evaluation of genetic resistance. Poult. Sci. 60, 2559–2566 (1981). · doi:10.3382/ps.0602559
  20. De Boer, G. F., Groenendal, J. E., Boerrigter, H. M., Kok, G. L. & Pol, J. M. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Dis. 30, 276–283 (1986). · doi:10.2307/1590529
  21. Burgess, S. C. & Davison, T. F. Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37. J. Virol. 76, 7276–7292 (2002). · doi:10.1128/jvi.76.14.7276-7292.2002
  22. Calnek, B. W. Pathogenesis of Marek's disease. In Marek's Disease (ed. Hirai, K.) 25–55 (Springer, Berlin, 2001). · doi:10.1007/978-3-642-56863-3_2
  23. Schumacher, D., Tischer, B. K., Fuchs, W. & Osterrieder, N. Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. J. Virol. 74, 11088–11098 (2000). This paper is the first description of an infectious MDV clone and the first characterization of an essential MDV gene. The establishment of various MDV strains as infectious clones in subsequent years has allowed a thorough elucidation of MDV replication and pathogenesis. · doi:10.1128/jvi.74.23.11088-11098.2000
  24. Petherbridge, L. et al. Replication-competent bacterial artificial chromosomes of Marek's disease virus: novel tools for generation of molecularly defined herpesvirus vaccines. J. Virol. 77, 8712–8718 (2003). · doi:10.1128/jvi.77.16.8712-8718.2003
  25. Reddy, S. M. et al. Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function. Proc. Natl Acad. Sci. USA 99, 7054–7059 (2002). · doi:10.1073/pnas.092152699
  26. Niikura, M., Dodgson, J. & Cheng, H. Direct evidence of host genome acquisition by the α-herpesvirus Marek's disease virus. Arch. Virol. 9 Sep 2005 (doi: 10.1007/s00705-005-0633-7). · doi:10.1007/s00705-005-0633-7
  27. Dorange, F., Tischer, B. K., Vautherot, J. F. & Osterrieder, N. Characterization of Marek's disease virus serotype 1 (MDV-1) deletion mutants that lack U L 46 to U L 49 genes: MDV-1 U L 49, encoding VP22, is indispensable for virus growth. J. Virol. 76, 1959–1970 (2002). · doi:10.1128/jvi.76.4.1959-1970.2002
  28. Osterrieder, N. et al. Generation and exploitation of infectious bacterial artificial chromosome (BAC) clones of animal herpesviruses. Berl. Munch. Tierarztl. Wochenschr. 116, 373–380 (2003).
  29. Tischer, B. K., Schumacher, D., Messerle, M., Wagner, M. & Osterrieder, N. The products of the U L 10 (gM) and the U L 49.5 genes of Marek's disease virus serotype 1 are essential for virus growth in cultured cells. J. Gen. Virol. 83, 997–1003 (2002). · doi:10.1099/0022-1317-83-5-997
  30. Schmutz, J. & Grimwood, J. Genomes: fowl sequence. Nature 432, 679–680 (2004). · doi:10.1038/432679a
  31. Schat, K. A., Schinazi, R. F. & Calnek, B. W. Cell-specific antiviral activity of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) against Marek's disease herpesvirus and turkey herpesvirus. Antiviral Res. 4, 259–270 (1984). · doi:10.1016/0166-3542(84)90031-7
  32. Shek, W. R., Calnek, B. W., Schat, K. A. & Chen, C. H. Characterization of Marek's disease virus-infected lymphocytes: discrimination between cytolytically and latently infected cells. J. Natl Cancer Inst. 70, 485–491 (1983).
  33. Baigent, S. J. & Davison, T. F. Development and composition of lymphoid lesions in the spleens of Marek's disease virus-infected chickens: association with virus spread and the pathogenesis of Marek's disease. Avian Pathol. 28, 287–300 (1999). · doi:10.1080/03079459994786
  34. Baigent, S. J., Ross, L. J. N. & Davison, T. F. Differential susceptibility to Marek's disease is associated with differences in number, but not phenotype or location, of pp38+ lymphocytes. J. Gen. Virol. 79, 2795–2802 (1998). · doi:10.1099/0022-1317-79-11-2795
  35. Carrozza, J. H., Fredrickson, T. N., Prince, R. P. & Luginbuhl, R. E. Role of desquamated epithelial cells in transmission of Marek's disease. Avian Dis. 17, 767–781 (1973). · doi:10.2307/1589045
  36. Johnson, E. A., Burke, C. N., Fredrickson, T. N. & DiCapua, R. A. Morphogenesis of Marek's disease virus in feather follicle epithelium. J. Natl Cancer Inst. 55, 89–99 (1975). · doi:10.1093/jnci/55.1.89
  37. Niikura, M. et al. MDV glycoprotein D is expressed in the feather follicle epithelium of infected chickens. Acta Virol. 43, 159–163 (1999).
  38. Peng, Q. H. & Shirazi, Y. Characterization of the protein product encoded by a splicing variant of the Marek's disease virus Eco-Q gene (Meq). Virology 226, 77–82 (1996). · doi:10.1006/viro.1996.0629
  39. Cui, X., Lee, L. F., Reed, W. M., Kung, H. J. & Reddy, S. M. Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency. J. Virol. 78, 4753–4760 (2004). · doi:10.1128/jvi.78.9.4753-4760.2004
  40. Isfort, R. J., Kung, H. J. & Velicer, L. F. Identification of the gene encoding Marek's disease herpesvirus A antigen. J. Virol. 61, 2614–2620 (1987). · doi:10.1128/jvi.61.8.2614-2620.1987
  41. Ross, L. J., Basarab, O., Walker, D. J. & Whitby, B. Serological relationship between a pathogenic strain of Marek's disease virus, its attenuated derivative and herpes virus of turkeys. J. Gen. Virol. 28, 37–47 (1975). · doi:10.1099/0022-1317-28-1-37
  42. Isfort, R. J., Stringer, R. A., Kung, H. J. & Velicer, L. F. Synthesis, processing, and secretion of the Marek's disease herpesvirus A antigen glycoprotein. J. Virol. 57, 464–474 (1986). · doi:10.1128/jvi.57.2.464-474.1986
  43. Tischer, B. K. et al. High-level expression of Marek's disease virus glycoprotein C is detrimental to virus growth in vitro. J. Virol. 79, 5889–5899 (2005). · doi:10.1128/jvi.79.10.5889-5899.2005
  44. Calnek, B. W., Schat, K. A., Ross, L. J. & Chen, C. L. Further characterization of Marek's disease virus-infected lymphocytes. II. In vitro infection. Int. J. Cancer 33, 399–406 (1984). · doi:10.1002/ijc.2910330319
  45. Schat, K. A., Chen, C. L., Shek, W. R. & Calnek, B. W. Surface antigens on Marek's disease lymphoblastoid tumor cell lines. J. Natl Cancer Inst. 69, 715–720 (1982).
  46. Schat, K. A., Chen, C. L., Calnek, B. W. & Char, D. Transformation of T-lymphocyte subsets by Marek's disease herpesvirus. J. Virol. 65, 1408–1413 (1991). · doi:10.1128/jvi.65.3.1408-1413.1991
  47. Lee, S. I., Ohashi, K., Morimura, T., Sugimoto, C. & Onuma, M. Re-isolation of Marek's disease virus from T cell subsets of vaccinated and non-vaccinated chickens. Arch. Virol. 144, 45–54 (1999). · doi:10.1007/s007050050484
  48. Takagi, M., Ohashi, K., Morimura, T., Sugimoto, C. & Onuma, M. Analysis of tumor suppressor gene p53 in chicken lymphoblastoid tumor cell lines and field tumors. J. Vet Med. Sci. 60, 923–929 (1998). · doi:10.1292/jvms.60.923
  49. Morimura, T., Ohashi, K., Sugimoto, C. & Onuma, M. Pathogenesis of Marek's disease (MD) and possible mechanisms of immunity induced by MD vaccine. J. Vet Med. Sci. 60, 1–8 (1998). · doi:10.1292/jvms.60.1
  50. Silver, S., Tanaka, A. & Nonoyama, M. Transcription of the Marek's disease virus genome in a nonproductive chicken lymphoblastoid cell line. Virology 93, 127–133 (1979). · doi:10.1016/0042-6822(79)90281-2
  51. Tanaka, A., Silver, S. & Nonoyama, M. Biochemical evidence of the nonintegrated status of Marek's disease virus DNA in virus-transformed lymphoblastoid cells of chicken. Virology 88, 19–24 (1978). · doi:10.1016/0042-6822(78)90105-8
  52. Maray, T., Malkinson, M. & Becker, Y. RNA transcripts of Marek's disease virus (MDV) serotype-1 in infected and transformed cells. Virus Genes 2, 49–68 (1988). · doi:10.1007/bf00569736
  53. Sugaya, K., Bradley, G., Nonoyama, M. & Tanaka, A. Latent transcripts of Marek's disease virus are clustered in the short and long repeat regions. J. Virol. 64, 5773–5782 (1990). · doi:10.1128/jvi.64.12.5773-5782.1990
  54. Cantello, J. L., Parcells, M. S., Anderson, A. S. & Morgan, R. W. Marek's disease virus latency-associated transcripts belong to a family of spliced RNAs that are antisense to the ICP4 homolog gene. J. Virol. 71, 1353–1361 (1997). · doi:10.1128/jvi.71.2.1353-1361.1997
  55. Morgan, R. W. et al. Marek's disease virus latency. In Marek's Disease (ed. Hirai, K.) 223–243 (Springer, Berlin, 2001). · doi:10.1007/978-3-642-56863-3_9
  56. Shigekane, B., Kawaguchi, Y., Shirakata, M., Sakaguchi, M. & Hirai, K. The bi-directional transcriptional promoters for the latency-relating transcripts of the pp38/pp24 mRNAs and the 1.8 kb-mRNA in the long inverted repeats of Marek's disease virus serotype 1 DNA are regulated by common promoter-specific enhancers. Arch. Virol. 144, 1893–1907 (1999). · doi:10.1007/s007050050713
  57. Kopacek, J., Ross, L. J., Zelnik, V. & Pastorek, J. The 132 bp repeats are present in RNA transcripts from 1.8 kb gene family of Marek disease virus-transformed cells. Acta Virol 37, 191–195 (1993).
  58. Gimeno, I. M. et al. The pp38 gene of Marek's disease virus (MDV) is necessary for cytolytic infection of B cells and maintenance of the transformed state but not for cytolytic infection of the feather follicle epithelium and horizontal spread of MDV. J. Virol. 79, 4545–4549 (2005). · doi:10.1128/jvi.79.7.4545-4549.2005
  59. Hayashi, M., Kawamura, T., Akaike, H., Arai, S. & Okui, T. Antisense oligonucleotide complementary to the BamHI-H gene family of Marek's disease virus induced growth arrest of MDCC-MSB1 cells in the S-phase. J. Vet Med. Sci. 61, 389–394 (1999). · doi:10.1292/jvms.61.389
  60. Kawamura, M. et al. The inhibitory effects of oligonucleotides, complementary to Marek's disease virus mRNA transcribed from the BamHI-H region, on the proliferation of transformed lymphoblastoid cells, MDCC-MSB1. J. Gen. Virol. 72, 1105–1111 (1991). · doi:10.1099/0022-1317-72-5-1105
  61. Hong, Y. & Coussens, P. M. Identification of an immediate-early gene in the Mareks-disease virus long internal repeat region which encodes a unique 14-kilodalton polypeptide. J. Virol. 68, 3593–3603 (1994). · doi:10.1128/jvi.68.6.3593-3603.1994
  62. Peng, F. Y., Specter, S., Tanaka, A. & Nonoyama, M. A 7-kDa protein encoded by the BamhI-H gene family of Mareks-disease virus is produced in lytically and latently infected-cells. Int. J. Oncol. 4, 799–802 (1994).
  63. Delecluse, H. J., Schuller, S. & Hammerschmidt, W. Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J. 12, 3277–3286 (1993). · doi:10.1002/j.1460-2075.1993.tb05997.x
  64. Liu, J. L. et al. Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2. J. Virol. 73, 4208–4219 (1999). · doi:10.1128/jvi.73.5.4208-4219.1999
  65. Qian, Z., Brunovskis, P., Lee, L., Vogt, P. K. & Kung, H. J. Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein. J. Virol. 70, 7161–7170 (1996). · doi:10.1128/jvi.70.10.7161-7170.1996
  66. Burgess, S. C. et al. Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). Proc. Natl Acad. Sci. USA 101, 13879–13884 (2004). In this paper, a link is made between Meq and overexpression of CD30, an important marker for Hodgkin's disease, underscoring the fact that MD is an excellent model for virus-induced oncogenesis. · doi:10.1073/pnas.0305789101
  67. Levy, A. M. et al. Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: a converging transforming pathway for avian oncoviruses. Proc. Natl. Acad. Sci. USA 102, 14831–14836 (2005). · doi:10.1073/pnas.0506849102
  68. Lupiani, B. et al. Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc. Natl Acad. Sci. USA 101, 11815–11820 (2004). A comprehensive and detailed analysis of the replication of MDV in vivo demonstrated that lytic replication is slightly reduced in the absence of Meq, but that tumours are completely absent, providing final proof of Meq's role in tumour formation in vivo. · doi:10.1073/pnas.0404508101
  69. Brown, A. C. et al. Interaction of MEQ and CtBP is critical for induction of lymphomas by Marek's disease virus. Proc. Natl Acad. Sci. USA 103, 1687–1692 (2006). · doi:10.1073/pnas.0507595103
  70. Maruo, S., Johannsen, E., Illanes, D., Cooper, A. & Kieff, E. Epstein–Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J. Virol. 77, 10437–10447 (2003). · doi:10.1128/jvi.77.19.10437-10447.2003
  71. Shamblin, C. E., Greene, N., Arumugaswami, V., Dienglewicz, R. L. & Parcells, M. S. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence. Vet. Microbiol. 102, 147–167 (2004). · doi:10.1016/j.vetmic.2004.06.007
  72. Lee, S. I., Takagi, M., Ohashi, K., Sugimoto, C. & Onuma, M. Difference in the meq gene between oncogenic and attenuated strains of Marek's disease virus serotype 1. J. Vet. Med. Sci. 62, 287–292 (2000). · doi:10.1292/jvms.62.287
  73. Witter, R. L. & Kreager, K. S. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease. Avian Dis. 48, 768–782 (2004). · doi:10.1637/7203-050304r
  74. Witter, R. L. Increased virulence of Marek's disease virus field isolates. Avian Dis. 41, 149–163 (1997). A detailed account of the changes in virulence of MDV strains over the decades is provided in a well standardized model. The relationship between use of MDV vaccines on the one hand and the increase in virulence and the change in tropism and disease manifestation on the other hand is discussed. · doi:10.2307/1592455
  75. Witter, R. L. Avian tumor viruses: persistent and evolving pathogens. Acta Vet. Hung. 45, 251–266 (1997).
  76. Witter, R. L. The changing landscape of Marek's disease. Avian Pathol. 27, S46–S53 (1998). · doi:10.1080/03079459808419292
  77. Gimeno, I. M. et al. Marek's disease virus infection in the brain: virus replication, cellular infiltration, and major histocompatibility complex antigen expression. Vet. Pathol. 38, 491–503 (2001). · doi:10.1354/vp.38-5-491
  78. Witter, R. L., Gimeno, I. M., Reed, W. M. & Bacon, L. D. An acute form of transient paralysis induced by highly virulent strains of Marek's disease virus. Avian Dis. 43, 704–720 (1999). · doi:10.2307/1592740
  79. Jarosinski, K. W., Yunis, R., O'Connell, P. H., Markowski-Grimsrud, C. J. & Schat, K. A. Influence of genetic resistance of the chicken and virulence of Marek's disease virus (MDV) on nitric oxide responses after MDV infection. Avian Dis. 46, 636–649 (2002). · doi:10.1637/0005-2086(2002)046[0636:iogrot]2.0.co;2
  80. Witter, R. L., Nazerian, K., Purchase, H. G. & Burgoyne, G. H. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus. Am. J. Vet. Res. 31, 525–538 (1970). This paper, together with the initial isolation of the MDV agent in cultured cells, was the starting point for MD vaccination and the overwhelming success of a worldwide control programme. · doi:10.2460/ajvr.1970.31.03.525
  81. King, D., Page, D., Schat, K. A. & Calnek, B. W. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines. Avian Dis. 25, 74–81 (1981). · doi:10.2307/1589828
  82. Rispens, B. H., van Vloten, H., Mastenbroek, N., Maas, J. L. & Schat, K. A. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis. 16, 126–138 (1972). · doi:10.2307/1588906
  83. Rispens, B. H., van Vloten, H., Mastenbroek, N., Maas, H. J. & Schat, K. A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16, 108–125 (1972). The authors isolated the first non-pathogenic variant of an MDV, which is currently the most efficacious vaccine and used worldwide. · doi:10.2307/1588905
  84. Levy, A. M., Heller, E. D., Leitner, G. & Davidson, I. Effect of native chicken interferon on MDV replication. Acta Virol. 43, 121–127 (1999).
  85. Markowski-Grimsrud, C. J. & Schat, K. A. Cytotoxic T lymphocyte responses to Marek's disease herpesvirus-encoded glycoproteins. Vet. Immunol. Immunopathol. 90, 133–144 (2002). · doi:10.1016/s0165-2427(02)00229-5
  86. Nazerian, K., Witter, R. L., Lee, L. F. & Yanagida, N. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus. Avian Dis. 40, 368–376 (1996). · doi:10.2307/1592234
  87. Tischer, B. K. et al. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. J. Gen. Virol. 83, 2367–2376 (2002). · doi:10.1099/0022-1317-83-10-2367
  88. Lee, L. F. et al. Characterization of a very virulent Marek's disease virus mutant expressing the pp38 protein from the serotype 1 vaccine strain CVI988/Rispens. Virus Genes 31, 73–80 (2005). · doi:10.1007/s11262-005-2202-2
  89. Cui, X. et al. A Marek's disease virus vIL-8 deletion mutant has attenuated virulence and confers protection against challenge with a very virulent plus strain. Avian Dis. 49, 199–206 (2005). · doi:10.1637/7277-091004
  90. Osterrieder, N. Sequence and initial characterization of the UL10 (glycoprotein M) and UL11 homologous genes of serotype 1 Marek's disease virus. Arch. Virol. 144, 1853–1863 (1999). · doi:10.1007/s007050050710
  91. Liu, J. L. et al. MEQ and v-IL8: cellular genes in disguise? Acta Virol. 43, 94–101 (1999).
  92. Qian, Z., Brunovskis, P., Rauscher, F., Lee, L. & Kung, H. J. Transactivation activity of Meq, a Mareks-disease herpesvirus bzip protein persistently expressed in latently infected transformed T-cells. J. Virol. 69, 4037–4044 (1995). · doi:10.1128/jvi.69.7.4037-4044.1995
  93. Jarosinski, K. W., Osterrieder, N., Nair, V. K. & Schat, K. A. Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a. J. Virol. 79, 11647–11659 (2005). · doi:10.1128/jvi.79.18.11647-11659.2005

Cited by

See all 411

Metadata

Authors
Osterrieder, N., Kamil, J. P., Schumacher, D., Tischer, B. K., & Trapp, S.
Venue
Nature Reviews Microbiology
Publisher
Springer Science and Business Media LLC
Published
2006-04-01
Volume
4
Issue
4
Pages
283-294
ISSN
  • 1740-1526 (ISSN-L)
  • 1740-1534
DOI
10.1038/nrmicro1382
OpenAlex
W2076176349
Cited by
411
References
44
FWCI
1.09
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Marek's disease virus: from miasma to model. https://app.cochat.ai/papers/10.1038/nrmicro1382
The paper
Osterrieder, N., Kamil, J. P., Schumacher, D., Tischer, B. K., & Trapp, S. (2006). Marek's disease virus: from miasma to model. Nature Reviews Microbiology. https://doi.org/10.1038/nrmicro1382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.